Key facts
- This page summarizes Todd Foley's Form 4 filing for Aktis Oncology, Inc. (AKTS).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 14 Jan 2026, 18:20.
Todd Foley - 12 Jan 2026 Form 4 Insider Report for Aktis Oncology, Inc. (AKTS)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- AKTS
- Reported as of
- 12 Jan 2026
- Net transaction value
- +$4,191,660
- SEC form
- 4
- Accepted by SEC
- 14 Jan 2026, 18:20:21 UTC
- Prior SEC filing
- 08 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /sTodd Foley
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Todd Foley filed Form 4 for Aktis Oncology, Inc. (AKTS) on 14 Jan 2026.
Change
- Previous filing in this sequence was filed on 08 Jan 2026.
- Current net transaction value: +$4,191,660.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001473930
Primary reporting owner
Foley Todd
- Relationship
- Director, 10%+ Owner
- Address
- C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
- Signature
- /sTodd Foley
- Signature date
- 14 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKTS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +597,391
- Change %
- Price
- Shares after
- 597,391
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3, F4
AKTS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,688,270
- Change %
- +450%
- Price
- Shares after
- 3,285,661
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F2, F3, F5, F6
AKTS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +716,872
- Change %
- +22%
- Price
- Shares after
- 4,002,533
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F2, F3, F7, F8
AKTS
transaction
Common Stock
Purchase
- Transaction value
- $4,191,660
- Shares
- +232,870
- Change %
- +5.8%
- Price
- $18.00
- Shares after
- 4,235,403
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F3, F9, F10
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKTS
transaction
Derivative
Series Seed Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -2,272,727
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 597,391
- Exercise price
- Footnotes
- F1, F2, F3
AKTS
transaction
Derivative
Series A Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -10,227,273
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 2,688,270
- Exercise price
- Footnotes
- F2, F3, F5
AKTS
transaction
Derivative
Series B Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -2,727,273
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 716,872
- Exercise price
- Footnotes
- F2, F3, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 10 footnotes
Footnote F1
The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.
Footnote F2
Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.
Footnote F3
The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F4
The shares are held as follows: 556,810 by BV 2018, 29,593 by BV 2018(B) and 10,988 by AM BV2018.
Footnote F5
The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.
Footnote F6
The shares are held as follows: 3,062,458 by BV 2018, 162,763 by BV 2018(B) and 60,440 by AM BV2018.
Footnote F7
The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.
Footnote F8
The shares are held as follows: 3,730,631 by BV 2018, 198,275 by BV 2018(B) and 73,627 by AM BV2018.
Footnote F9
The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B) and 4,284 by AM BV2018.
Footnote F10
The shares are held as follows: 3,950,528 by BV 2018, 206,964 by BV 2018(B) and 77,911 by AM BV2018.